rs201105958
Positions:
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 3P and 1B. PM2PP5BP4
The NM_138694.4(PKHD1):c.5498C>T(p.Ser1833Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000156 in 1,613,922 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.000092 ( 0 hom., cov: 33)
Exomes 𝑓: 0.00016 ( 0 hom. )
Consequence
PKHD1
NM_138694.4 missense
NM_138694.4 missense
Scores
1
8
10
Clinical Significance
Conservation
PhyloP100: 2.06
Genes affected
PKHD1 (HGNC:9016): (PKHD1 ciliary IPT domain containing fibrocystin/polyductin) The protein encoded by this gene is predicted to have a single transmembrane (TM)-spanning domain and multiple copies of an immunoglobulin-like plexin-transcription-factor domain. Alternative splicing results in two transcript variants encoding different isoforms. Other alternatively spliced transcripts have been described, but the full length sequences have not been determined. Several of these transcripts are predicted to encode truncated products which lack the TM and may be secreted. Mutations in this gene cause autosomal recessive polycystic kidney disease, also known as polycystic kidney and hepatic disease-1. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 2 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 6-52017512-G-A is Pathogenic according to our data. Variant chr6-52017512-G-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 496898.We mark this variant Likely_pathogenic, oryginal submissions are: {Uncertain_significance=4, Pathogenic=1, Likely_pathogenic=5}. Variant chr6-52017512-G-A is described in Lovd as [Likely_pathogenic]. Variant chr6-52017512-G-A is described in Lovd as [Pathogenic].
BP4
Computational evidence support a benign effect (MetaRNN=0.40701413). . Strength limited to SUPPORTING due to the PP5.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PKHD1 | NM_138694.4 | c.5498C>T | p.Ser1833Leu | missense_variant | 34/67 | ENST00000371117.8 | NP_619639.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PKHD1 | ENST00000371117.8 | c.5498C>T | p.Ser1833Leu | missense_variant | 34/67 | 1 | NM_138694.4 | ENSP00000360158.3 | ||
PKHD1 | ENST00000340994.4 | c.5498C>T | p.Ser1833Leu | missense_variant | 34/61 | 5 | ENSP00000341097.4 |
Frequencies
GnomAD3 genomes AF: 0.0000920 AC: 14AN: 152190Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
14
AN:
152190
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000167 AC: 42AN: 251130Hom.: 0 AF XY: 0.000214 AC XY: 29AN XY: 135726
GnomAD3 exomes
AF:
AC:
42
AN:
251130
Hom.:
AF XY:
AC XY:
29
AN XY:
135726
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000162 AC: 237AN: 1461614Hom.: 0 Cov.: 32 AF XY: 0.000169 AC XY: 123AN XY: 727144
GnomAD4 exome
AF:
AC:
237
AN:
1461614
Hom.:
Cov.:
32
AF XY:
AC XY:
123
AN XY:
727144
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000919 AC: 14AN: 152308Hom.: 0 Cov.: 33 AF XY: 0.000121 AC XY: 9AN XY: 74472
GnomAD4 genome
AF:
AC:
14
AN:
152308
Hom.:
Cov.:
33
AF XY:
AC XY:
9
AN XY:
74472
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
0
ALSPAC
AF:
AC:
1
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
2
ExAC
AF:
AC:
27
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:7Uncertain:6
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Autosomal recessive polycystic kidney disease Pathogenic:4Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Mar 23, 2018 | The PKHD1 c.5498C>T (p.Ser1833Leu) missense variant has been reported in three studies and is found in three individuals with autosomal recessive polycystic kidney disease, two in a compound heterozygous state and one in whom zygosity was not specified, but who also carried two other variants (Rossetti et al. 2003; Gunay-Aygun et al. 2010; Tong et al. 2016). Probands exhibited phenotypes including medullary sponge kidney, Caroli's disease, and congenital hepatic fibrosis (Rossetti et al. 2003; Gunay-Aygun et al. 2010). Control data are unavailable for this variant, which is reported at a frequency of 0.000293 in the European (non-Finnish) population of the Genome Aggregation Database. Based on the evidence, the p.Ser1833Leu variant is classified as a variant of unknown significance but suspicious for pathogenicity for autosomal recessive polycystic kidney disease. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Oct 24, 2017 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | - | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory of Molecular Genetics, Children's Memorial Health Institute | Sep 25, 2020 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 17, 2024 | This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 1833 of the PKHD1 protein (p.Ser1833Leu). This variant is present in population databases (rs201105958, gnomAD 0.03%). This missense change has been observed in individuals with polycystic kidney disease (PMID: 12846734, 19914852, 27752906, 33282801, 33940108, 35812281). ClinVar contains an entry for this variant (Variation ID: 496898). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PKHD1 protein function with a negative predictive value of 95%. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 27, 2023 | Variant summary: PKHD1 c.5498C>T (p.Ser1833Leu) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00017 in 251130 control chromosomes (gnomAD). This frequency is not higher than estimated for a pathogenic variant in PKHD1 causing Polycystic Kidney And Hepatic Disease (0.00017 vs 0.0071), allowing no conclusion about variant significance. c.5498C>T has been reported in the literature in multiple individuals affected with Polycystic Kidney And Hepatic Disease, and segregated with disease within families (e.g. Burgmaier_2021). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Five ClinVar submitters (evaluation after 2014) cite the variant as uncertain significance and one ClinVar submitter (evaluation after 2014) cites it as likey pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
not provided Pathogenic:1Uncertain:3
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Oct 01, 2024 | Observed phase unknown with a second variant in a patient with congenital hepatic fibrosis, Caroli's disease, and medullary sponge kidney in published literature (PMID: 12846734); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 26489027, 30809968, 14741187, 34405919, 33282801, 19914852, 27752906, 33940108, 35812281, 38051388, 12846734) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Dec 28, 2016 | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
PKHD1-related disorder Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 28, 2024 | The PKHD1 c.5498C>T variant is predicted to result in the amino acid substitution p.Ser1833Leu. This variant was reported with a second missense variant in an adult (38 years old) patient with cholangitis, medullary sponge kidney and cyst in a genetic study of patients with autosomal recessive polycystic kidney disease (ARPKD) (Rossetti et al. 2003. PubMed ID: 12846734). In addition, this variant was reported with a pathogenic (splice or exon-level deletion) variant in two unrelated families affected by ARPKD (Table S1 of Ajiri et al. 2022. PubMed ID: 35812281). Moreover, we have previously observed this variant together with a frameshift variant in two unrelated children tested for polycystic kidney disease at PreventionGenetics (internal data). This variant is reported in 0.030% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as likely pathogenic. Of note, this variant has been suggested to be incompletely penetrant (Mikó et al. 2021. PubMed ID: 34405919). - |
Polycystic kidney disease 4 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 27, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Uncertain
T
BayesDel_noAF
Pathogenic
CADD
Benign
DANN
Uncertain
DEOGEN2
Uncertain
D;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Benign
T;T
M_CAP
Benign
D
MetaRNN
Benign
T;T
MetaSVM
Uncertain
D
MutationAssessor
Benign
L;L
PrimateAI
Benign
T
PROVEAN
Uncertain
D;D
REVEL
Uncertain
Sift
Uncertain
D;D
Sift4G
Uncertain
T;T
Polyphen
D;D
Vest4
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at